Marc 6-7, 2017
March 29th – April 2nd 2017
May 18, 2017
Eyal Baror will speech in this conference - Wednesday, May 31 10:40 - Treatments for Alzheimer's and Cognitive Disorders
Globally, the population continues to age and the number of dementia patients keeps expanding. Ongoing efforts to develop disease modifying therapies have been plagued with failures. What new avenues are being pursued to address the growing global need? Will novel diagnostics allow us to initiate treatments earlier? What non-pharmacological options are in development?
Panelists: Casey Lynch, CEO, Cortexyme
Mark Gurney, CEO, Tetra Discovery Partners
Eyal Baror, CEO and President, Neuronix
31st May – 1st June 2017
December 8-10, 2016
neuroAD is an investigational device currently not commercially available in the United States.
neuroAD is CE-cleared and commercially available for the treatment of mild to moderate Alzheimer’s Disease in Europe.